These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2784783)

  • 1. Human lymphokine-activated killer cells develop syngeneic killing ability.
    Gallagher G; Findlay J; al-Azzawi FA
    Immunology; 1989 Mar; 66(3):471-4. PubMed ID: 2784783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.
    Beckner SK; Maluish AE; Longo DL
    Cancer Res; 1987 Oct; 47(20):5504-8. PubMed ID: 3498534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
    Komatsu F; Ishiguro K
    Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
    Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS; Hargrove ME; Ting CC
    J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC; Hargrove ME; Yun YS
    J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.